2018 Fiscal Year Final Research Report
A systematic approach to achieving glioblastoma cure via targeting glioma stem cells: PART2
| Project/Area Number |
15H04946
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Neurosurgery
|
|---|
| Research Institution | Yamagata University |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
OKADA MASASHI
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Keywords | グリオブラストーマ |
|---|
| Outline of Final Research Achievements |
In this project, to further advance to clinical application the achievements attained in our previous studies on glioma stem cells, we searched for drugs that can enhance the effect of metformin and, through the drug repurposing strategy, JNK inhibitors that are effective against cancer stem cells. As a result, we identified AS602801 and CEP-1347 as such JNK inhibitors with known safety profiles in humans. Moreover, we have unexpectedly succeeded in identifying a drug that has selective cytotoxicity against glioma stem cells.
|
| Free Research Field |
脳神経外科学
|
| Academic Significance and Societal Importance of the Research Achievements |
がん（悪性新生物）は長年にわたり我が国の死亡原因圧倒的第１位を維持しており、がんの克服は国家的にも重要な課題である。本課題はがんの再発・転移の主要因と考えられているがん幹細胞に着目し、そのがん幹細胞に作用することで再発・転移を防ぎがん根治が期待できるがん幹細胞治療薬開発を目指そうとする課題である。本課題ではすでにヒトへの安全性が確認されている薬剤の中からがん幹細胞に有効な薬剤を見出し、しかもその効果を前臨床試験レベルで確認ずみであるなど、がん根治薬の臨床応用に向けて大きな一歩となりうる成果を挙げた。
|
